Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on February 7, 2017, to report the filing of a prospectus supplement. This supplement relates to the potential resale of up to 2,804,948 shares of the Company's common stock by certain stockholders. This filing is a procedural step in the context of a pre-existing shelf registration statement and indicates that some shareholders may be looking to sell their holdings in the open market. The company also provided an opinion from its legal counsel, O’Melveny & Myers LLP, confirming the legality of the common stock being registered for resale. This filing does not represent a new equity offering by the company itself, but rather facilitates the liquidity for existing shareholders under a previously established registration.
Key Highlights
- 1Prospectus supplement filed for the resale of up to 2,804,948 shares of common stock by named stockholders.
- 2Filing is in connection with a prior automatic shelf registration statement on Form S-3.
- 3Indicates potential for existing shareholders to sell a significant block of shares.
- 4Legal opinion from O’Melveny & Myers LLP regarding the legality of the registered shares was filed as an exhibit.
- 5This is a routine filing to enable secondary market sales by specific shareholders, not a new capital raise by the company.